AEterna signs collaborative deal with sanofi-aventis

Guest Contributor
March 16, 2009

Quebec City-based AEterna Zentaris Inc has entered a major collaborative agreement with sanofi-aventis to develop, commercialize and license Cetrorelix — its drug compound for the treatment of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The terms of the agreement are for the US market, where more than 20 million men suffer from the affliction. Sanofi-aventis will pay AEterna $30 million up front with the potential for an additional $135 million if certain regulatory and commercial milestones are achieved. AEterna is also entitled to escalating double-digit royalties on future net sales. Cetrorelix is currently in Phase 3 trials and sanofi-aventis may perform future Phase 3b and Phase 4 clinical trials. The first efficacy results of the Phase 3 trials are expected in Q3/09 with an NDA filing planned for 2010….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.